Oric net loss narrows 14.03% to $41.49 million in Q2 FY26 - ORIC News | RalliesOric net loss narrows 14.03% to $41.49 million in Q2 FY26
O
ORIC• Cash position and pipeline update
- Cash, cash equivalents and investments totaled USD 387.6 million at June 30, with runway expected into 2H 2028.
- Oric initiated the Himalayas-1 global Phase 3 trial of rinzimetostat plus darolutamide in mCRPC; Bayer will supply darolutamide at no cost.
- Jacob M. Chacko said the Phase 3 start brings ORIC closer to a “potentially practice-changing therapy” for prostate cancer.
Quarterly loss and operating expenses
- Oric Pharmaceuticals posted a Q2 net loss of USD 41.49 million, widening from USD 36.36 million a year earlier.
- Operating loss widened to USD 45.3 million as R&D expenses rose 18.7% to USD 36.3 million.
